40 ERIE STREET, CAMBRIDGE, MA
Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Financial Results, Changes in Board, Management or Compensation
Intellia Reports Positive 3-Year Data on Lonvo-z for HAE
News
Material disclosure
Intellia Reports Positive Data from Nexiguran Study in ATTR Amyloidosis Patients
Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Confidential Treatment Order
Correspondence
Submission Upload